Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?-Reference-Cited by-同舟云学术

Will Direct Oral Anticoagulants Have a Chance in Prosthetic Valves?

Published:2020-02-26 Issue: Volume:15 Page:
ISSN:1758-3764
Container-title:European Cardiology Review
language:en
Short-container-title:Eur Cardiol

Author:

Abdelnabi Mahmoud¹,Almaghraby Abdallah²,Saleh Yehia³

Affiliation:

1. Cardiology and Angiology Unit, Department of Clinical and Experimental Internal Medicine, Medical Research Institute, University of Alexandria, Egypt

2. Department of Cardiology, Faculty of Medicine, University of Alexandria, Egypt

3. Department of Cardiology, Faculty of Medicine, University of Alexandria, Egypt; Michigan State University, East Lansing, MI, US

Abstract

Although there are abundant data highlighting the safety and efficacy of direct oral anticoagulants, to date, recent guidelines have limited their use to stroke prevention in patients with non-valvular AF, as well as in the prevention and treatment of venous thromboembolism and pulmonary embolism. Encouraging data about the off-label use of direct oral anticoagulants have been shown in several other indications, such as intracardiac thrombi, left ventricular thrombi and left atrial appendage, but a large sector of patients are still not addressed, such as valvular and prosthetic patients.

Publisher

Radcliffe Group Ltd

Subject

Cardiology and Cardiovascular Medicine

Reference12 articles.

1. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2019;16:e66–93. https://doi.org/10.1016/j.jacc.2019.01.011; PMID: 30703431.

2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893–962. https://doi.org/10.1093/ejcts/ezw313; PMID: 27663299.

3. Kim JY, Kim SH, Myong JP, et al. Outcomes of direct oral anticoagulants in patients with mitral stenosis. J Am Coll Cardiol 2019;73:1123–31. https://doi.org/10.1016/j.jacc.2018.12.047; PMID: 30871695.

4. Abdelnaby M, Almaghraby A, Abdelkarim O, et al. The role of rivaroxaban in left ventricular thrombi. Anatol J Cardiol 2019;21:47–50. https://doi.org/10.14744/AnatolJCardiol.2018.48313; PMID: 30587707.

5. Mujer M, Kandola SK, Saleh Y. Rarecase of biventricular thrombi complicating pulmonary embolism. BMJ Case Rep 2019;12. https://doi.org/10.1136/bcr-2019-229698; PMID: 31061185.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Present Knowledge on Direct Oral Anticoagulant and Novel Oral Anti Coagulants and Their Specific Antidotes: A Comprehensive Review Article;Current Problems in Cardiology;2023-02

2. Switching from warfarin to direct-acting oral anticoagulants: it is time to move forward!;The Egyptian Heart Journal;2022-03-28

3. Direct Oral Anticoagulants Versus Vitamin K Antagonists in the Treatment of Left Ventricular Thrombi;American Journal of Cardiovascular Drugs;2021-11-05

4. Commentary: Battle of the bioprosthetic valve blood thinners;The Journal of Thoracic and Cardiovascular Surgery;2021-02

5. Comparison of outcomes of direct-acting oral anticoagulants vs. vitamin K antagonists in patients with bioprosthetic heart valves or valve repair: a systematic review and meta-analysis;EUR REV MED PHARMACO;2021